StocksFundsScreenerSectorsWatchlists
MEDS

MEDS - Trxade Group Inc Stock Price, Fair Value and News

9.96USD+0.41 (+4.29%)Delayed as of 28 Mar 2024, 01:03 pm ET

Market Summary

MEDS
USD9.96+0.41
Delayedas of 28 Mar 2024, 01:03 pm
4.29%

MEDS Stock Price

View Fullscreen

MEDS RSI Chart

MEDS Valuation

Market Cap

11.5M

Price/Earnings (Trailing)

-1.62

Price/Sales (Trailing)

0.54

Price/Free Cashflow

480.03

MEDS Price/Sales (Trailing)

MEDS Profitability

Operating Margin

75.97%

Return on Equity

-61.3%

Return on Assets

-32.72%

Free Cashflow Yield

0.21%

MEDS Fundamentals

MEDS Revenue

Revenue (TTM)

9.4M

Rev. Growth (Yr)

-31.34%

Rev. Growth (Qtr)

0.15%

MEDS Earnings

Earnings (TTM)

-7.1M

Earnings Growth (Yr)

-600.81%

Earnings Growth (Qtr)

-78.5%

Breaking Down MEDS Revenue

52 Week Range

0.2519.70
(Low)(High)

Last 7 days

-16.4%

Last 30 days

424.4%

Last 90 days

387.3%

Trailing 12 Months

6586.1%

How does MEDS drawdown profile look like?

MEDS Financial Health

Current Ratio

0.61

MEDS Investor Care

Shares Dilution (1Y)

92.42%

Diluted EPS (TTM)

-6.78

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
202310.5M9.4M00
202210.1M11.5M11.3M11.4M
202118.0M13.3M9.5M9.9M
20208.1M12.8M16.8M17.1M
20194.5M5.6M7.0M7.4M
20183.1M3.2M3.3M3.8M
20172.8M2.9M3.0M3.0M
20162.4M2.7M3.0M3.2M
20151.9M2.8M4.1M2.1M
20141.1M1.2M1.4M1.5M
2013000955.9K

Tracking the Latest Insider Buys and Sells of Trxade Group Inc

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Jan 05, 2024
patel prashant
acquired
-
-
150,000
interim cfo and director
Jan 05, 2024
ajjarapu surendra k
acquired
-
-
150,000
chairman and ceo
Jan 16, 2023
peterson michael l
acquired
-
-
100,000
-
Dec 30, 2022
newell a. jeffrey
acquired
-
-
237,186
-
Dec 13, 2022
huffman janet
acquired
-
-
50,000
cfo, pao, pfo
Sep 01, 2022
pope charles l
acquired
-
-
54,525
-
Sep 01, 2022
ajjarapu surendra k
acquired
-
-
51,724
ceo
Sep 01, 2022
patel prashant
acquired
-
-
8,620
president and coo
Sep 01, 2022
fell donald g.
acquired
-
-
54,525
-
Sep 01, 2022
huffman janet
acquired
-
-
21,551
cfo, pao, pfo

1–10 of 50

Which funds bought or sold MEDS recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Feb 14, 2024
Royal Bank of Canada
unchanged
-
-
-
-%
Feb 14, 2024
BANK OF AMERICA CORP /DE/
unchanged
-
-27.00
78.00
-%
Feb 13, 2024
Tower Research Capital LLC (TRC)
added
92.57
3,243
10,906
-%
Feb 13, 2024
Qube Research & Technologies Ltd
reduced
-50.00
-886
520
-%
Feb 09, 2024
WELLS FARGO & COMPANY/MN
added
166
21.00
42.00
-%
Feb 07, 2024
CONCOURSE FINANCIAL GROUP SECURITIES, INC.
sold off
-
-
-
-%
Jan 18, 2024
Blue Trust, Inc.
unchanged
-
-2,000
3,000
-%

1–7 of 7

Are Funds Buying or Selling MEDS?

Are funds buying MEDS calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own MEDS
No. of Funds

Unveiling Trxade Group Inc's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 14, 2024
armistice capital, llc
4.99%
65,502
SC 13G/A
Feb 14, 2023
armistice capital, llc
9.99%
977,103
SC 13G
Oct 19, 2022
patel prashant
22.4%
2,092,371
SC 13D/A
Oct 19, 2022
ajjarapu surendra k
24.5%
2,288,824
SC 13D/A
Jun 16, 2020
ajjarapu surendra k
28.8%
2,217,724
SC 13D/A
Apr 21, 2020
ajjarapu surendra k
31.4%
2,418,296
SC 13D/A
Oct 08, 2019
r.s.n., llc
7.7%
3e+06
SC 13G/A
Oct 08, 2019
r.s.n., llc
7.7%
3e+06
SC 13G/A

Recent SEC filings of Trxade Group Inc

View All Filings
Date Filed Form Type Document
Mar 06, 2024
8-K
Current Report
Feb 26, 2024
SEC STAFF ACTION
SEC STAFF ACTION
Feb 16, 2024
8-K
Current Report
Feb 14, 2024
SC 13G/A
Major Ownership Report
Jan 17, 2024
8-K
Current Report
Jan 16, 2024
4
Insider Trading
Jan 16, 2024
4
Insider Trading
Jan 16, 2024
10-Q
Quarterly Report
Jan 11, 2024
8-K
Current Report

Peers (Alternatives to Trxade Group Inc)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
380.6B
85.2B
-0.84% 1.87%
10.83
4.47
6.46% 95.94%
333.8B
60.1B
-3.08% 18.97%
914.53
5.55
1.40% -97.49%
156.9B
46.5B
-0.94% -29.07%
-113.02
3.37
42.59% -114.62%
153.4B
28.2B
-2.65% 20.18%
22.84
5.44
7.09% 2.52%
91.0B
27.1B
1.44% -6.08%
16.06
3.35
-0.60% 23.36%
16.2B
15.8B
6.68% 47.26%
-28.08
1.02
6.17% 76.47%
MID-CAP
4.6B
1.7B
-15.20% 8.04%
12.8
2.74
49.61% 324.78%
4.3B
4.7B
-2.22% -15.29%
-335.7
0.92
4.58% 90.97%
3.8B
8.8B
12.34% 25.79%
-6.47
0.44
7.79% -163.11%
2.1B
644.4M
-19.16% 20.49%
15.22
3.25
29.14% 50.51%
SMALL-CAP
1.8B
700.5M
20.31% -
-1.29
2.63
16.26% -147.49%
24.2M
70.0M
1.33% -38.14%
0.35
0.34
-19.54% 888.31%
18.7M
-
-10.40% 69.70%
-1.01
0.22
2882.68% -138.52%
14.8M
111.1M
-18.24% -6.20%
-0.93
0.13
-10.43% 84.90%
929.3K
20.0M
-54.17% -94.76%
-0.07
0.05
137.71% 66.04%

Trxade Group Inc News

Latest updates
TradingView06 Mar 202408:00 am
TradingView20 Feb 202401:14 pm
AlphaStreet12 Feb 202408:00 am

Trxade Group Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
(In Thousands)
Income Statement (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q3
Revenue-100.0%-2,2512,2482,5292,4003,2793,2402,3882,5501,8983,0531,9946,3326,5932,2031,6962,3111,9161,5131,294847
Cost Of Revenue---------------------2.00
Gross Profit3.6%1,7051,6451,5571,5101,3721,1711,3361,2401,2818411,3831331,9292,0051,6401,2501,3111,1631,147847845
Operating Expenses28.1%2,5501,9901,9043,8631,5912,2742,3042,0232,5773,4112,028----------
  S&GA Expenses101.3%614305377345230547651-1169176484481,7131,7832,5401,4521,2391,1331,0319751,157753
Interest Expenses39.3%25218162.001961309.001.002.006.009.007.007.007.007.008.006.0013.0016.0018.0018.0013.00
Income Taxes----------------------
Net Income-78.5%-3,525-1,974-677-908-503-1,112-965-784-1,301-2,578-651-2,312138-542180-49528.0058.00125-18794.00
Net Income Margin-74.4%-0.75*-0.43*-0.31*-0.30*-0.30*-0.36*-0.56*-0.54*-0.72*-0.41*-0.19*-0.15*-0.04*--------
Free Cashflow-291.7%-603315-9451,216-590-1,192-1,014-440-752-705-724-7292,483--------
Balance Sheet
(In Thousands)
Balance Sheet
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q3
Assets478.2%21,6543,7454,0383,7104,4805,6725,8405,7665,5146,8969,6939,79311,85411,73211,4745,5715,8555,8553,2992,228306
  Current Assets164.8%5,5482,0952,3862,0932,3733,3473,5974,3745,1896,5369,1559,22110,64310,1239,7953,8034,3151,9521,4911,466306
    Cash Equivalents-95.4%34.007461,2001,0953229621,8713,1233,5724,5205,2095,9206,6484,1517,7012,8723,359540534870127
  Inventory1777.1%3,02716112668.0076.0012727456.0095.001394701,2581,6471,81936857.0063.0054762.0080.00100
  Net PPE383.3%28860.0062.0065.0068.0071.0074.0099.0013.0015.0016116215015119717511.0013.0014.0015.00-
  Goodwill-5,129-----------726726726726726726726726726
Liabilities100.3%10,0945,0403,3833,3673,3333,8682,9531,9968971,1091,4921,1141,0271,5811,8371,4311,9642,3382,0811,383239
  Current Liabilities113.3%9,0924,2632,5502,1472,0612,5461,5969266558611,2388425357209515219561,085808860239
Shareholder's Equity993.0%11,560-1,2946557631,3571,8052,8883,7704,6175,7878,2028,67910,82710,1519,6374,1403,8911,3401,218845326
  Retained Earnings1.7%-21,529-21,900-19,900-19,719-18,800-18,300-17,213-16,247-15,463-14,161-11,583-10,931-8,619-8,757-8,215-8,395-7,900-7,927-7,985-8,1117.00
  Additional Paid-In Capital60.7%33,09020,58620,56020,48320,19320,11220,08320,01820,08019,94819,78519,61119,44618,90917,85212,53611,7909,2689,2048,956-
Shares Outstanding20.0%819683681626547545545544542541540540505--------
Minority Interest-----420-42.43-16.6918.00--------------
Float------16,922---16,922---21,541---2,653---
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q3
Cashflow From Operations-283.6%-603329-9311,230-576-1,178-1,000-426-738-691-710-7152,483-3,571-410-18240446.00-12542.0085.00
Cashflow From Investing-299.8%-207-51.80333-114-55.73-28023.00-----14.00---23.50-82.25--40.00-210--
Cashflow From Financing115.9%115-725681-303-7.86550-274--210--1.0013.0022.005,264-2222,415-166*500300

MEDS Income Statement

2023-09-30
Consolidated Statements of Operations (Unaudited) - USD ($)
3 Months Ended9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Income Statement [Abstract]    
Revenues$ 2,058,028$ 2,055,803$ 5,919,786$ 7,993,805
Cost of sales353,450683,3751,072,9343,991,234
Gross profit1,704,5781,372,4284,846,8524,002,571
Operating expenses:    
Wage and salary expense698,030849,3712,077,3622,949,386
Professional fees418,29482,710782,286256,807
Accounting and legal expense408,957191,007782,495567,086
Technology expense410,612238,5771,010,374690,875
General and administrative expense613,834229,5261,264,9021,392,130
Total operating expenses2,549,7271,591,1915,917,4195,856,284
Operating loss(845,149)(218,763)(1,070,567)(1,853,713)
Nonoperating income (expense)    
Change in fair value of warrant liability925,320(443,308)
Interest income8,3964,1988,396
Gain (loss) on disposal of assets2,200
Interest expense(251,778)(130,107)(494,904)(140,626)
Total nonoperating income (expense)673,542(121,711)(934,014)(130,030)
Net loss from continuing operations(171,607)(340,474)(2,004,581)(1,983,743)
Net loss on discontinued operations(3,353,507)(188,268)(4,123,028)(623,096)
Net loss(3,525,114)(528,742)(6,127,609)(2,606,839)
Net loss attributable to TRxADE Health, Inc.(3,525,114)(503,003)(6,127,609)(2,546,913)
Net loss attributable to non-controlling interests$ (25,739)$ (59,926)
Net loss per common share from continuing operations    
Basic$ (0.22)$ (0.57)$ (2.83)$ (3.52)
Diluted(0.07)(0.57)(0.87)(3.51)
Net loss per common share from discontinued operations    
Basic(4.35)(0.34)(5.82)(1.14)
Diluted(1.42)(0.34)(1.79)(1.14)
Net loss attributable to common stockholders    
Basic(4.57)(0.91)(8.65)(4.66)
Diluted$ (1.49)$ (0.91)$ (2.66)$ (4.64)
Weighted average common shares outstanding    
Basic771,192549,977708,116546,879
Diluted2,363,233551,7242,300,157548,626

MEDS Balance Sheet

2023-09-30
Consolidated Balance Sheets (Unaudited) - USD ($)
Sep. 30, 2023
Dec. 31, 2022
Current Assets  
Cash$ 34,031$ 1,094,891
Accounts receivable, net850,103649,263
Inventory3,026,91868,448
Prepaid assets246,093104,462
Notes receivable1,275,000
Other receivables115,684
Current assets of discontinued operations176,057
Total Current Assets5,547,8292,093,121
Property plant and equipment, net287,92065,214
Deposits49,03149,031
Intangible assets, net9,451,562
Goodwill5,129,116
Other assets
Operating lease right-of-use assets1,188,3851,051,815
Noncurrent assets of discontinued operations450,845
Total Assets21,653,8433,710,026
Current Liabilities  
Accounts payable1,328,599527,984
Accrued liabilities386,024271,230
Other current liabilities412,39067,517
Contingent funding liabilities452,348108,036
Current portion of operating lease liabilities251,087196,872
Notes payable— related party, current portion5,230,000 
Warrant liability1,031,841588,533
Current liabilities of discontinued operations219,952
Total Current Liabilities9,092,2892,146,791
Long Term Liabilities  
Operating lease liabilities, net of current portion976,869887,035
Notes payable- related party, net of current portion25,000 
Total Liabilities10,094,1583,367,159
Stockholders’ Equity  
Common stock, $0.00001 par value; 6,666,667 shares authorized; 818,961 and 626,247 shares issued and outstanding, as of September 30, 2023 and December 31, 2022, respectively86
Additional paid-in capital33,089,65220,482,666
Retained deficit(21,529,975)(19,719,536)
Total TRxADE Health Inc. Stockholders’ Equity11,559,685763,136
Non-controlling interest in subsidiary(420,269)
Total Stockholders’ Equity11,559,685342,867
Total Liabilities and Stockholders’ Equity21,653,8433,710,026
Series A Preferred Stock [Member]  
Stockholders’ Equity  
Preferred stock, value
Series B Preferred Stock [Member]  
Stockholders’ Equity  
Preferred stock, value
Nonrelated Party [Member]  
Current Liabilities  
Notes payable— related party, current portion5,230,000
Long Term Liabilities  
Notes payable- related party, net of current portion25,000
Related Party [Member]  
Current Liabilities  
Notes payable— related party, current portion166,667
Long Term Liabilities  
Notes payable- related party, net of current portion$ 333,333
MEDS
TRxADE HEALTH, Inc. operates as a health services IT company in the United States. The company focuses on digitalizing the retail pharmacy experience by optimizing drug procurement, prescription journey, and patient engagement. It operates the TRxADE drug procurement marketplace, which offers price transparency, purchasing capabilities, and other value-added services; and offers patient centric telehealth services under the Bonum Health brand name. The company was formerly known as Trxade Group, Inc. and changed its name to TRxADE HEALTH, Inc. in June 2021. TRxADE HEALTH, Inc. is based in Lutz, Florida.
 CEO
 WEBSITEwww.trxadehealth.com
 EMPLOYEES33

Trxade Group Inc Frequently Asked Questions


What is the ticker symbol for Trxade Group Inc? What does MEDS stand for in stocks?

MEDS is the stock ticker symbol of Trxade Group Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Trxade Group Inc (MEDS)?

As of Wed Mar 27 2024, market cap of Trxade Group Inc is 11.51 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of MEDS stock?

You can check MEDS's fair value in chart for subscribers.

What is the fair value of MEDS stock?

You can check MEDS's fair value in chart for subscribers. The fair value of Trxade Group Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Trxade Group Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for MEDS so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Trxade Group Inc a good stock to buy?

The fair value guage provides a quick view whether MEDS is over valued or under valued. Whether Trxade Group Inc is cheap or expensive depends on the assumptions which impact Trxade Group Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for MEDS.

What is Trxade Group Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed Mar 27 2024, MEDS's PE ratio (Price to Earnings) is -1.62 and Price to Sales (PS) ratio is 0.54. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. MEDS PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Trxade Group Inc's stock?

In the past 10 years, Trxade Group Inc has provided 0.806 (multiply by 100 for percentage) rate of return.